Sign In
Buy ALNY
$297.69
+5.53 (+1.89%)
At Close: Jun 09, 2026
Alnylam Q1 Earnings Beat Estimates, Amvuttra Sales Drive Y/Y Growth
01:10pm, Friday, 01'st May 2026
ALNY beats Q1 earnings and revenue estimates as Amvuttra sales surge 187%, driving 96% revenue growth and offsetting declines in collaborator revenue and Onpattro sales.
Alnylam Pharmaceuticals: The RNAi Leader Continues To Grind Through A Quieter Year
12:25pm, Friday, 01'st May 2026
Alnylam Pharmaceuticals remains well-positioned in the TTR amyloidosis market, with a robust franchise and reliable clinical asset generation. Q1 2026 results showed 150% year-over-year TTR franchise
Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2026 Earnings Call Transcript
12:51pm, Thursday, 30'th Apr 2026
Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2026 Earnings Call Transcript
Alnylam (ALNY) Reports Q1 Earnings: What Key Metrics Have to Say
11:01am, Thursday, 30'th Apr 2026
Although the revenue and EPS for Alnylam (ALNY) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street
Alnylam Pharmaceuticals (ALNY) Tops Q1 Earnings and Revenue Estimates
10:26am, Thursday, 30'th Apr 2026
Alnylam Pharmaceuticals (ALNY) came out with quarterly earnings of $1.99 per share, beating the Zacks Consensus Estimate of $1.43 per share. This compares to a loss of $0.01 per share a year ago.
Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress
08:00am, Thursday, 30'th Apr 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended Ma
Alnylam (ALNY) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates
10:15am, Wednesday, 29'th Apr 2026
Beyond analysts' top-and-bottom-line estimates for Alnylam (ALNY), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
11:01am, Monday, 27'th Apr 2026
Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Alnylam (ALNY) is Poised to Beat Earnings Estimates Again
01:11pm, Thursday, 23'rd Apr 2026
Alnylam (ALNY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Alnylam Pharmaceuticals (ALNY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
11:03am, Thursday, 23'rd Apr 2026
Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Brown Advisory Large-Cap Growth Strategy Q1 2026 Portfolio Review
06:45am, Friday, 17'th Apr 2026
Netflix outperformed during the period as investor concerns around a potential acquisition of Warner Bros. Discovery subsided. Microsoft lagged during the quarter despite reporting strong underlying r
Alnylam to Webcast Conference Call Discussing First Quarter 2026 Financial Results
08:00am, Thursday, 16'th Apr 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter endi
Massachusetts Financial Services Co. MA Boosts Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY
05:28am, Monday, 13'th Apr 2026
Massachusetts Financial Services Co. MA lifted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) by 38.9% during the fourth quarter, according to its most recent disclosure with the
Melissa Mclaughlin Sells 1,624 Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock
04:03am, Thursday, 09'th Apr 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY - Get Free Report) insider Melissa Mclaughlin sold 1,624 shares of the business's stock in a transaction that occurred on Thursday, April 2nd. The shares we
Melissa Mclaughlin Sells 2,286 Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock
04:02am, Thursday, 09'th Apr 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY - Get Free Report) insider Melissa Mclaughlin sold 2,286 shares of the company's stock in a transaction that occurred on Monday, April 6th. The stock was so
